PDS Biotechnology‘s patent involves vaccine compositions with cationic lipids as adjuvants to induce humoral and cellular immune responses in mammals. The method includes administering the vaccine with multi-epitope viral antigens, enhancing CD 8+ T-cell response by at least 2-fold. GlobalData’s report on PDS Biotechnology gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights PDS Biotechnology Corp - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on PDS Biotechnology, Recombinant viral vaccines was a key innovation area identified from patents. PDS Biotechnology's grant share as of February 2024 was 30%. Grant share is based on the ratio of number of grants to total number of patents.

Vaccine composition with cationic lipid for immune response enhancement

Source: United States Patent and Trademark Office (USPTO). Credit: PDS Biotechnology Corp

A recently granted patent (Publication Number: US11911465B2) discloses a method for inducing both a humoral immune response and a CD 8+ T cell response in mammals by administering a vaccine composition containing a lipid and at least one multi-epitope viral antigen. The lipid in the composition is a cationic lipid, specifically R-DOTAP, which enhances the CD 8+ T-cell response by at least 2-fold compared to the viral antigen alone. This method aims to improve the efficacy of vaccines by stimulating both arms of the immune system simultaneously.

Furthermore, the patent claims cover the use of this method for treating diseases in mammals, particularly humans, by administering the vaccine composition containing the cationic lipid and multi-epitope viral antigen. The antigen, which can include influenza antigens, is modified to increase hydrophobicity, potentially improving its immunogenicity. By enhancing antigen cross-presentation, this method aims to elicit robust humoral and CD 8+ T cell responses, crucial for effective immune protection. Overall, this patented method offers a promising approach to developing vaccines that can trigger a comprehensive immune response against pathogens, potentially leading to more effective disease prevention and treatment strategies.

To know more about GlobalData’s detailed insights on PDS Biotechnology, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies